1 completed, 1 terminated. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Alstrom Syndrome: new trials by email Literature Review of Alstrom Syndrome trials Research Report on Alstrom Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity Setmelanotide, Placebo - Bardet Biedl Syndrome (BBS), Alström Syndrome (AS) | Phase 3 | Completed | Rhythm Pharmaceuticals, Inc. | 52 | 2018-11-23 | 2023-12-01 |
| Open-Label Rollover Study of PBI 4050 in Subjects With Alström Syndrome PBI-4050 - Alström Syndrome | Phase 2 / Phase 3 | Terminated | Liminal BioSciences Ltd. | 10 | 2017-10-09 | 2020-11-03 |
Bardet-Biedl Syndrome (1) · Obesity (1)
Abnormalities, Multiple (2) · Ciliopathies (2) · Congenital Abnormalities (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Eye Diseases (2) · Eye Diseases, Hereditary (2) · Genetic Diseases, Inborn (2) · Hereditary Sensory and Motor Neuropathy (2) · Heredodegenerative Disorders, Nervous System (2) · Nervous System Diseases (2) · Nervous System Malformations (2) · Neurodegenerative Diseases (2) · Neuromuscular Diseases (2) · Peripheral Nervous System Diseases (2) · Polyneuropathies (2)
setmelanotide (1) · setogepram (1)
Liminal BioSciences Ltd. (1) · Rhythm Pharmaceuticals, Inc. (1)
United Kingdom (2) · Canada (1) · France (1) · Puerto Rico (1) · Spain (1) · United States (1)
David Meeker, MD (1)
PMID 34013094, PMID 36356613, PMID 36647077, PMID 36961653, PMID 41703984, PMID 42821228
2018 (1)